News
The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...
Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discoverin ...
Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...
Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is primarily treated through surgical resection. For ...
Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, safety, and impact on patient quality of life.
Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral CSF1R inhibitor vimseltinib, newly branded Romvimza, could take significant ...
The FDA has approved Romvimza (vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor.
The Food and Drug Administration’s approval of Turalio for tenosynovial giant cell tumors may offer significantly improved clinical benefit for select patients with these rare, benign tumors.
The FDA has approved Turalio (pexidartinib; Daiichi Sankyo) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional ...
“TGCT (tenosynovial giant cell tumor) can cause debilitating symptoms for patients such as pain, stiffness and limitation of movement,” Richard Pazdur, MD, director of the Oncology Center of ...
Tenosynovial giant cell tumor (TGCT) is a benign but locally aggressive tumor that, in some cases, can be painful, disabling or disfiguring.
An investigational drug, PLX3397 (Plexxikon, Daiichi Sankyo), has shown prolonged tumor regression in patients with tenosynovial giant cell tumor (TGCT), a rare disorder of the joints that leaves ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results